- Home
- DPRO vs CARM Comparison
DPRO vs CARM Comparison
Compare DPRO & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DPRO
- CARM
- Stock Information
- Founded
- DPRO 1998
- CARM 2016
- Country
- DPRO Canada
- CARM United States
- Employees
- DPRO N/A
- CARM N/A
- Industry
- DPRO Aerospace
- CARM Biotechnology: Pharmaceutical Preparations
- Sector
- DPRO Industrials
- CARM Health Care
- Exchange
- DPRO Nasdaq
- CARM Nasdaq
- Market Cap
- DPRO 36.2M
- CARM 8.4M
- IPO Year
- DPRO N/A
- CARM N/A
- Fundamental
- Price
- DPRO $3.12
- CARM $0.41
- Analyst Decision
- DPRO Strong Buy
- CARM Hold
- Analyst Count
- DPRO 2
- CARM 5
- Target Price
- DPRO $5.25
- CARM $0.90
- AVG Volume (30 Days)
- DPRO 2.5M
- CARM 42.2M
- Earning Date
- DPRO 08-12-2025
- CARM 08-07-2025
- Dividend Yield
- DPRO N/A
- CARM N/A
- EPS Growth
- DPRO N/A
- CARM N/A
- EPS
- DPRO N/A
- CARM N/A
- Revenue
- DPRO $4,716,450.00
- CARM $19,964,000.00
- Revenue This Year
- DPRO $94.01
- CARM N/A
- Revenue Next Year
- DPRO $95.14
- CARM N/A
- P/E Ratio
- DPRO N/A
- CARM N/A
- Revenue Growth
- DPRO 7.90
- CARM 32.45
- 52 Week Low
- DPRO $1.55
- CARM $0.14
- 52 Week High
- DPRO $6.09
- CARM $1.42
- Technical
- Relative Strength Index (RSI)
- DPRO 58.98
- CARM 51.65
- Support Level
- DPRO $2.96
- CARM $0.37
- Resistance Level
- DPRO $3.32
- CARM $0.44
- Average True Range (ATR)
- DPRO 0.29
- CARM 0.07
- MACD
- DPRO 0.04
- CARM -0.01
- Stochastic Oscillator
- DPRO 81.48
- CARM 10.37
About DPRO Draganfly Inc.
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.